|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||86.36 - 86.96|
|52-week range||74.92 - 95.82|
|Beta (5Y monthly)||0.40|
|PE ratio (TTM)||8.96|
|Earnings date||29 Jul 2021|
|Forward dividend & yield||3.20 (3.70%)|
|Ex-dividend date||05 May 2021|
|1y target est||82.62|
Dr. Alice Chen, General Internist in Washington, D.C. & Former Executive Director with Doctors for America, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus pandemic.
Yahoo Finance’s Anjalee Khemlani reports the latest updates on the coronavirus.
The French-based pharmaceutical company Sanofi (NASDAQ: SNY) has been flying under the radar over the past few years as companies like AbbVie, Bristol Myers Squibb, and Merck have dominated the space through the tremendous success of their drugs. Sanofi was actually a creation of several different companies, including Aventis, Synthélabo, Hoechst, Rhône-Poulenc Rorer, and several others. Through mergers and acquisitions (M&A) we got the Sanofi we know today.